300 related articles for article (PubMed ID: 18534276)
41. A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
Tita C; Gilbert EM; Van Bakel AB; Grzybowski J; Haas GJ; Jarrah M; Dunlap SH; Gottlieb SS; Klapholz M; Patel PC; Pfister R; Seidler T; Shah KB; Zieliński T; Venuti RP; Cowart D; Foo SY; Vishnevsky A; Mitrovic V
Eur J Heart Fail; 2017 Oct; 19(10):1321-1332. PubMed ID: 28677877
[TBL] [Abstract][Full Text] [Related]
42. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
43. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction.
Badano LP; Albanese MC; De Biaggio P; Rozbowsky P; Miani D; Fresco C; Fioretti PM
J Am Soc Echocardiogr; 2004 Mar; 17(3):253-61. PubMed ID: 14981424
[TBL] [Abstract][Full Text] [Related]
44. Effect of short-term infusive dobutamine therapy on thyroid hormone profile and hemodynamic parameters in patients with acute worsening heart failure and low-triiodothyronine syndrome.
D'Aloia A; Vizzardi E; Bugatti S; Rovetta R; Bonadei I; Del Magro F; Curnis A; Dei Cas L
J Investig Med; 2012 Aug; 60(6):907-10. PubMed ID: 22722568
[TBL] [Abstract][Full Text] [Related]
45. Hemodynamic effects of intravenous butopamine in congestive heart failure.
Thompson MJ; Huss P; Unverferth DV; Fasola A; Leier CV
Clin Pharmacol Ther; 1980 Sep; 28(3):324-34. PubMed ID: 7408391
[TBL] [Abstract][Full Text] [Related]
46. Reverse left ventricular remodeling by intermittent dobutamine infusions and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy.
Nanas JN; Tsagalou EP; Nanas SN; Terrovitis JV; Tsolakis EJ; Toumanidis S; Papazoglou PD; Alexopoulos GP; Kanakakis J; Anastasiou-Nana MI
Int J Cardiol; 2006 Apr; 108(2):237-43. PubMed ID: 16183152
[TBL] [Abstract][Full Text] [Related]
47. Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
Ferrari P; Micheletti R; Valentini G; Bianchi G
Med Hypotheses; 2007; 68(5):1120-5. PubMed ID: 17113239
[TBL] [Abstract][Full Text] [Related]
48. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
49. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
[TBL] [Abstract][Full Text] [Related]
50. Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure.
Kobayashi S; Susa T; Tanaka T; Murakami W; Fukuta S; Okuda S; Doi M; Wada Y; Nao T; Yamada J; Okamura T; Yano M; Matsuzaki M
Circ J; 2012; 76(7):1646-53. PubMed ID: 22481100
[TBL] [Abstract][Full Text] [Related]
51. [Hemodynamic effects of milrinone on patients with chronic congestive heart failure: a multicenter study. Cooperative Group for Phase II Clinical Trial of Milrinone].
Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):599-602. PubMed ID: 8697925
[TBL] [Abstract][Full Text] [Related]
52. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure.
Ishiki R; Ishihara T; Izawa H; Nagata K; Hirai M; Yokota M
J Cardiovasc Pharmacol; 2000 Jun; 35(6):897-905. PubMed ID: 10836724
[TBL] [Abstract][Full Text] [Related]
53. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure.
Adamson PB; Vanoli E; Mattera GG; Germany R; Gagnol JP; Carminati P; Schwartz PJ
J Cardiovasc Pharmacol; 2003 Aug; 42(2):169-73. PubMed ID: 12883318
[TBL] [Abstract][Full Text] [Related]
54. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
[TBL] [Abstract][Full Text] [Related]
55. Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure.
Asanoi H; Ishizaka S; Kameyama T; Ishise H; Sasayama S
J Cardiovasc Pharmacol; 1994 Feb; 23(2):268-74. PubMed ID: 7511757
[TBL] [Abstract][Full Text] [Related]
56. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
57. Acute intravenous infusion of an adenosine regulating agent improves left ventricular function in dogs with advanced heart failure.
Wang M; Gupta RC; Rastogi S; Kohli S; Zhang K; Lanfear DE; Sabbah HN
Cardiovasc Drugs Ther; 2013 Dec; 27(6):489-98. PubMed ID: 23907235
[TBL] [Abstract][Full Text] [Related]
58. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
Pflugfelder PW; O'Neill BJ; Ogilvie RI; Beanlands DS; Tanser PH; Tihal H; Mizgala HF; Fitchett DH; Kostuk WJ
Can J Cardiol; 1991; 7(1):5-10. PubMed ID: 2025794
[TBL] [Abstract][Full Text] [Related]
59. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
[TBL] [Abstract][Full Text] [Related]
60. Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold.
Gobbini M; Armaroli S; Banfi L; Benicchio A; Carzana G; Ferrari P; Giacalone G; Marazzi G; Moro B; Micheletti R; Sputore S; Torri M; Zappavigna MP; Cerri A
Bioorg Med Chem; 2010 Jun; 18(12):4275-99. PubMed ID: 20494582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
